Craft

Artemis Therapeutics

Revenue

$311 K

FY, 2022

Artemis Therapeutics Summary

Company Summary

Overview
Artemis Therapeutics (formerly known as New York Global Innovations) is a biopharmaceutical company that engages in the development of agents for the prevention and treatment of severe and potentially life-threatening infectious diseases. Its lead drug candidate, Artemisone, is a potent antiparasitic drug for the treatment of malaria.
Type
Private
Status
Active
Founded
1997
HQ
New York, NY, US | view all locations
Website
https://www.artemis-therapeutics.com/
Cybersecurity rating
Sectors

Key People

  • Brian Culley

    Brian Culley, Chief Executive Officer

  • Dana Wolf

    Dana Wolf, Chief Medical Officer

    • Chanan Morris

      Chanan Morris, Chief Financial Officer

    LocationsView all

    2 locations detected

    • New York, NY HQ

      United States

      18 E 16th St #307

    • San Diego, CA

      United States

    Artemis Therapeutics Financials

    Summary Financials

    Revenue (Q3, 2023)
    $176.0K
    Gross profit (Q3, 2023)
    $167.0K
    Net income (Q3, 2023)
    ($128.0K)
    Cash (Q3, 2023)
    $1.0K
    EBIT (Q3, 2023)
    ($153.0K)

    Footer menu